Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WEST PHARMACEUTICAL SERVICES, INC.

(WST)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WEST PHARMACEUTICAL SERVICES : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K/A)

08/24/2021 | 08:42am EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 19, 2021, the Company elected Molly Joseph to its Board as its newest member. With the addition of Ms. Joseph, the Board increased in size to 11 directors. Ms. Joseph is expected to participate on the Finance Committee and Innovation and Technology Committee of the Board.

Ms. Joseph, 47, is the former CEO of UnitedHealthcare Global, a role she served in for more than a decade, and former Executive Vice President of UnitedHealth Group. During her 16-year tenure at UnitedHealth Group, she pioneered the establishment of their global health business into one of the largest health benefits and medical delivery businesses outside of the United States. As CEO of UnitedHealthcare Global, she had oversight of more than 50 hospitals and several hundred ambulatory centers which served over 9 million patients and 7 million insurance members. Ms. Joseph also directed UnitedHealth Group in strategy and corporate development, where she led acquisitions and business transactions. Prior to joining UnitedHealth Group, she focused on business transactions as an investment banker and a corporate attorney.

Ms. Joseph serves on the Board of Directors of First Solar and the Board of Trustees at Santa Clara University. She is a long-time advisor to Children's Heartlink, a global nonprofit organization for pediatric cardiac care and also serves on the Board of Directors of Young Voices of Austin, a nonprofit organization focused on the advancement of children from diverse backgrounds.

Ms. Joseph will be entitled to the customary compensation arrangements for the Company's non-employee directors, which currently consists of a $90,000 annual retainer and an annual restricted stock unit grant of $190,000. Each element of Ms. Joseph's compensation will be prorated for her period of service. In addition, she will be eligible to participate in the Company's Director Deferred Compensation Plan. The Company's most recent proxy statement, filed with the Securities and Exchange Commission on March 24, 2021, describes these arrangements under the heading "Director Compensation".

Ms. Joseph will enter into our standard form of indemnification agreement, the form of which was included as Exhibit 10.1 to our Current Report on Form 8-K filed on January 6, 2009.

There were no arrangements or understandings between Ms. Joseph and any other person pursuant to which she was elected as a director, and there are and have been no transactions since the beginning of the Company's last fiscal year, or currently proposed, between the Company and Ms. Joseph.

Item 7.01 Regulation FD Disclosure.

On August 23, 2021, the Company issued a press release announcing the appointment of Ms. Joseph to the Board. A copy of the corrected press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.







                                       2

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.

(d)        Exhibit No.        Description
            99.1              West Pharmaceutical Services, Inc. Corrected Press Release, dated
                              August 23, 2021.
            104               The cover page from the Company's Current Report on Form 8-K, dated
                              August 19, 2021, formatted in Inline XBRL.




                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about WEST PHARMACEUTICAL SERVICES, INC.
11/11West to Participate in Upcoming Investor Conferences
PR
11/09WEST PHARMACEUTICAL SERVICES, INC. : Ex-dividend day for
FA
10/28WEST PHARMACEUTICAL SERVICES INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
AQ
10/28Tranche Update on West Pharmaceutical Services, Inc.'s Equity Buyback Plan announced on..
CI
10/28West Pharmaceutical Services, Inc. Reports Earnings Results for the Third Quarter and N..
CI
10/28West Announces Third-Quarter 2021 Results and Declares Fourth-Quarter 2021 Dividend - F..
PU
10/28WEST PHARMACEUTICAL SERVICES INC : Results of Operations and Financial Condition, Regulati..
AQ
10/28Q3 2021 West Pharmaceutical Service Earnings Presentation
PU
10/28WEST PHARMACEUTICAL : Q3 Earnings Snapshot
AQ
10/28West Pharmaceutical Services Earnings, Sales Jump in Q3; Lifts FY21 Revenue/EPS Guidanc..
MT
More news
Analyst Recommendations on WEST PHARMACEUTICAL SERVICES, INC.
More recommendations